The Hantavirus Scare Brought 3 Covid-Era Stocks Back in the Spotlight
The hantavirus outbreak on the MV Hondius lifted one mRNA chief 36% off May lows earlier than profit-taking trimmed the rally. The temporary transfer reactivated the pandemic-prep commerce throughout medical shares, placing three Covid-era shares again on the 2026 comeback watchlist.
Each setup carries a unique sign. One title has already moved on to the mRNA platform power. Another builds an inverse base as the biodefense contractor. The third presents a contrarian play loaded with bears. May 2026 is when every chart picks a facet.
Note: mRNA, brief for messenger RNA, is the vaccine platform behind the COVID-19 photographs, delivering genetic directions to cells as a substitute of utilizing a reside virus.
Moderna (NASDAQ: MRNA)
Among the Covid-era stocks rotating back into focus, Moderna inventory rallied 36.08% from $43.69 on May 1 to $59.45 on May 11. Volume rose alongside worth all through the climb, confirming shopping for strain quite than brief masking.
Want extra insights like this? Sign up for Editor Harsh Notariya’s Daily Newsletter here.
Three catalysts drove the transfer. Q1 2026 income grew 260% year-over-year to $389 million; the firm disclosed a hantavirus vaccine collaboration with the US Army Medical Research Institute of Infectious Diseases; and Phase 3 mRNA-1010 flu knowledge have been published in the New England Journal of Medicine.
Moderna’s worth now sits close to $54.05, consolidating in what resembles the deal with of a cup-and-handle continuation sample. The cup backside anchors at $43.69, and the rim sits close to $59.45.
The deal with is forming above the 20-day Exponential Moving Average (EMA), a pattern indicator that weights latest worth motion extra closely, presently at $50.50.
Cup-and-handle patterns can fail if the deal with retraces deeper than half the cup, which might put the bullish thesis in query.
The sample stays legitimate so long as $51.17 holds. A each day shut beneath opens the technique to the 20-day EMA at $50.50 and the 50-day EMA at $49.75. A break beneath $43.69 invalidates the sample solely.
A each day shut above $54.91 begins the deal with breakout. A transfer above $60.96, which aligns with the upward-sloping neckline and the 0.618 Fibonacci degree, confirms the breakout and tasks a measured transfer to $81.46, roughly 33.59% above present ranges.
Moderna already took its leg up. A smaller title (EBS) behind the US pandemic stockpile has not.
Emergent BioSolutions (NYSE: EBS)
Among the Covid-era shares with the steepest drawdowns, Emergent stock manufactured Johnson & Johnson’s COVID-19 vaccine at its Baltimore Bayview facility beneath a $480 million contract. A 2021 contamination scandal that ruined 15 million doses then triggered a multi-year de-rating.
The stock corrected 44.36% from $14.07 to $7.53 earlier this yr. The set off was Emergent guiding FY26 income to $720-760 million on March 1, beneath consensus.
A second leg adopted on April 30, when Q1 2026 income fell 30% year-over-year to $156.1 million, pushed by weaker gross sales of anthrax and smallpox medical countermeasures.
That second dip created the head of an inverse head-and-shoulders sample. The left shoulder fashioned close to $7.82 in late March. The head dipped to $7.53 in early May. The proper shoulder is now forming at $8.33 with visibly weaker promoting strain. That weakening strain suggests the de-rating might have exhausted.
Inverse head-and-shoulders patterns fail when the proper shoulder dips beneath the head, which might put the ground in query.
A each day shut beneath $8.33 weakens the construction. A break beneath $7.53 invalidates the sample solely.
A each day shut above $10.02, which aligns with the neckline and the 0.786 Fibonacci degree, confirms the breakout. The measured transfer tasks 25.76% upside towards $12.65, with the prior high at $14.07 capping the prolonged goal.
Emergent’s sample is ready. The remaining chart reveals the contrarian mRNA title loaded with bear positioning.
BioNTech (NASDAQ: BNTX)
Among the Covid-era stocks with the most direct mRNA platform pedigree, (*3*) The companions delivered 2.6 billion doses throughout 165 nations in 2021. Peak income hit €18.98 billion that yr.
Since March 10, BNTX has carved a typical head-and-shoulders sample. The left shoulder fashioned in mid-March close to $100. The head peaked at $113.55 in early April. The proper shoulder is now forming at $93.63, simply above a neckline at $92.39.
The contrarian learn sits in the Chaikin Money Flow (CMF), a proxy for institutional flows. Since February 20, the worth has trended decrease, whereas the CMF has trended increased off its low. That bullish divergence usually precedes false breakdowns.
Positioning knowledge backs the contrarian setup. BioNTech reported a Q1 2026 web lack of $2.28 per share on May 5.
The put-call ratio, which compares bearish put choices to bullish name choices, now sits at 2.23 by quantity and 1.15 by open curiosity. That excessive bear skew creates short-squeeze gas if $92.39 holds.
A each day shut beneath $92.39 confirms a breakdown towards $86.64. The subsequent helps sit at $79.31 and $72.36, the full measured transfer goal. A each day shut above $100.47 begins the contrarian play by invalidating the proper shoulder. A transfer above $113.55 negates the total bearish sample.
Head-and-shoulders patterns fail when the proper shoulder breaks the head, invalidating the bearish setup fully. For now, $92.39 separates this contrarian Covid-era inventory’s rebound from a $72.36 measured transfer draw back.
The put up The Hantavirus Scare Brought 3 Covid-Era Stocks Back in the Spotlight appeared first on BeInCrypto.